Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Development of chemotherapeutics in oncology: is there anything new?

Development of chemotherapeutics in oncology: is there anything new? editorial memo (2017) 10:119–120 DOI 10.1007/s12254-017-0350-4 Development of chemotherapeutics in oncology: is there anything new? Holger Rumpold · Thomas Winder Received: 7 August 2017 / Accepted: 8 August 2017 / Published online: 7 September 2017 © Springer-Verlag GmbH Austria 2017 In a decade where the dynamic development of tar- achieved by the regional application of chemotherapy, getedtherapies andmodulationof the immune sys- for example Hepatic Artery Infusion (HAI) in colorec- tem for treating cancer has dramatically changed and tal cancer, on the one hand or by the tricky binding of dominates the armamentarium of an oncologist, the the well-known anti-microtubule substance emtasine topic the authors of this minireview series have been to the antibody trastuzumab, which specifically tar- confronted was challenging: is there anything new in gets Her2-positive cancer cells on the other hand. For the development of classical cytostatic drugs and their some indications, like pancreatic cancer or colorec- indications? tal cancer, it could be shown that “more aggressive Despite living in the area of “modern oncology”, is more effective”. The combination of oxaliplatin, there are indeed indications where chemotherapy irinotecan and 5-Fluorouracil (5FU) in the FOLFIRI- remains the mainstay of treatment in all stages of NOX or the http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Development of chemotherapeutics in oncology: is there anything new?

Loading next page...
 
/lp/springer-journals/development-of-chemotherapeutics-in-oncology-is-there-anything-new-2f5Joc1IIZ
Publisher
Springer Journals
Copyright
2017 Springer-Verlag GmbH Austria
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-017-0350-4
Publisher site
See Article on Publisher Site

Abstract

editorial memo (2017) 10:119–120 DOI 10.1007/s12254-017-0350-4 Development of chemotherapeutics in oncology: is there anything new? Holger Rumpold · Thomas Winder Received: 7 August 2017 / Accepted: 8 August 2017 / Published online: 7 September 2017 © Springer-Verlag GmbH Austria 2017 In a decade where the dynamic development of tar- achieved by the regional application of chemotherapy, getedtherapies andmodulationof the immune sys- for example Hepatic Artery Infusion (HAI) in colorec- tem for treating cancer has dramatically changed and tal cancer, on the one hand or by the tricky binding of dominates the armamentarium of an oncologist, the the well-known anti-microtubule substance emtasine topic the authors of this minireview series have been to the antibody trastuzumab, which specifically tar- confronted was challenging: is there anything new in gets Her2-positive cancer cells on the other hand. For the development of classical cytostatic drugs and their some indications, like pancreatic cancer or colorec- indications? tal cancer, it could be shown that “more aggressive Despite living in the area of “modern oncology”, is more effective”. The combination of oxaliplatin, there are indeed indications where chemotherapy irinotecan and 5-Fluorouracil (5FU) in the FOLFIRI- remains the mainstay of treatment in all stages of NOX or the

Journal

memo - Magazine of European Medical OncologySpringer Journals

Published: Sep 1, 2017

There are no references for this article.